Cannonau Corp. (CNNC) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.00 means the share price is 0.00 times one year of earnings per share; the S&P 500 usually sits near 20-25. Beta 1.52: the stock has moved about 52% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCannonau Corp. (CNNC) trades at $0.0003. Cannonau Corp. focuses on developing cannabidiol-based products. The company, formerly Pacific Blue Energy Corp., changed its name in August 2019 and is based in Skaneateles, New York. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for CNNC: CNNC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNNC against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
CNNC: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Cannonau Corp. (CNNC) Healthcare & Pipeline Overview
Cannonau Corp., a small-cap company in the specialty and generic drug manufacturing sector, focuses on developing cannabidiol-based products. Formerly Pacific Blue Energy Corp., the company operates from Skaneateles, New York, and faces competition in the rapidly evolving CBD market.
What Is the Investment Thesis for CNNC?
Cannonau Corp. presents a speculative investment opportunity within the high-growth CBD market. The company's small size and limited operating history introduce significant risks. Key value drivers include successful product development and market penetration within the competitive CBD landscape. The company's ability to secure funding and navigate regulatory hurdles will be critical for long-term viability. With a market capitalization of $0.00B and a P/E ratio of 0.00, traditional valuation metrics offer limited insight. The company's beta of 1.52 indicates higher volatility compared to the broader market. Investors should carefully consider the risks associated with investing in a small, OTC-listed company in a rapidly evolving industry.
Based on FMP financials and quantitative analysis
CNNC Key Highlights
Cannonau Corp. focuses on the development of cannabidiol (CBD) based products, tapping into the growing market for alternative health solutions.
- The company was formerly known as Pacific Blue Energy Corp., indicating a strategic shift in business focus towards the healthcare sector in August 2019.
- Cannonau Corp. is based in Skaneateles, New York, operating with a small team of 4 employees.
- The company's market capitalization is $0.00B, reflecting its early stage and potential for growth or risk.
- Cannonau Corp. trades on the OTC market, which typically involves higher risk and lower liquidity compared to major exchanges.
Who Are CNNC's Competitors?
CNNC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AVCNF Avicanna Inc. | $0.08 | 0.00% | $10.6M | 529-signal |
| PLNH Planet 13 Holdings Inc. | $0.13 | -7.14% | $42.7M | 429-signal |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| ZYBT Zhengye Biotechnology Holding Limited | $1.59 | +1.27% | $75.4M | 465-pillar |
| CWBHF Charlotte's Web Holdings, Inc. | $0.35 | +6.23% | $93.9M | 519-signal |
| AAWH Ascend Wellness Holdings, Inc. | $0.49 | +1.36% | $98.7M | 439-signal |
| BGM BGM Group Ltd. | $0.28 | +0.92% | $105M | 455-pillar |
| MEDXF Medexus Pharmaceuticals Inc. | $3.59 | -1.40% | $114M | 479-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are CNNC's Key Strengths?
Focus on the growing CBD market.
- Potential for innovative product development.
- Strategic shift towards healthcare applications.
- Small size allows for agility and adaptability.
What Are CNNC's Weaknesses?
Limited financial resources.
- Small team and limited operational capacity.
- Lack of established brand recognition.
- Dependence on a single product category (CBD).
What Could Drive CNNC Stock Higher?
Potential regulatory changes in key markets could create new opportunities for CBD products.
- Increasing consumer awareness and acceptance of CBD may drive demand for Cannonau Corp.'s products.
- Successful development and launch of new CBD formulations could boost revenue and market share.
- Strategic partnerships with established healthcare companies could expand distribution channels.
- Positive clinical trial results for CBD applications could enhance product credibility.
What Are the Key Risks for CNNC?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger companies in the CBD market.
- Evolving regulatory landscape could restrict the sale or marketing of CBD products.
- Negative publicity or safety concerns related to CBD could damage consumer confidence.
- Fluctuations in the price of CBD raw materials could impact profitability.
- Limited financial resources may hinder Cannonau Corp.'s ability to compete effectively.
What Are the Growth Opportunities for CNNC?
- Expansion of Product Line: Cannonau Corp. can expand its product line beyond basic CBD offerings to include specialized formulations targeting specific health conditions. The market for condition-specific CBD products is growing rapidly, with a potential market size of $5 billion by 2028. This expansion requires investment in research and development, but could significantly increase revenue and market share. The timeline for launching new products is estimated at 12-18 months, contingent on regulatory approvals and successful clinical trials.
- Strategic Partnerships: Forming strategic partnerships with established healthcare companies or retailers can provide Cannonau Corp. with access to wider distribution channels and increased brand recognition. The market for CBD products through established retail channels is projected to reach $8 billion by 2027. Partnering with a major retailer could provide immediate access to this market. The timeline for establishing such partnerships is estimated at 6-12 months, depending on negotiation and due diligence processes.
- Online Sales and Marketing: Developing a strong online presence and implementing effective digital marketing strategies can help Cannonau Corp. reach a broader customer base and build brand awareness. The online CBD market is expected to reach $6 billion by 2026. Investing in search engine optimization (SEO) and social media marketing can drive traffic to the company's website and increase online sales. The timeline for implementing these strategies is ongoing, with continuous optimization and adaptation required to maintain a competitive edge.
- Geographic Expansion: Expanding operations beyond the current base in Skaneateles, New York, to new geographic markets can unlock significant growth opportunities. The global CBD market is projected to reach $47 billion by 2028. Targeting specific regions with favorable regulatory environments and high consumer demand can drive revenue growth. The timeline for geographic expansion is estimated at 12-24 months, depending on regulatory approvals and market entry strategies.
- Research and Development: Investing in research and development to develop innovative CBD formulations and delivery methods can provide Cannonau Corp. with a competitive advantage. The market for novel CBD formulations is growing rapidly, with a potential market size of $3 billion by 2027. Developing patented formulations can protect the company's intellectual property and create a barrier to entry for competitors. The timeline for developing and patenting new formulations is estimated at 24-36 months, requiring significant investment in research and clinical trials.
What Are CNNC's Competitive Advantages?
- Proprietary CBD formulations (if any).
- Brand recognition and customer loyalty (if established).
- Strategic partnerships with distributors or retailers.
- Intellectual property protection through patents (if any).
What Does CNNC Do?
Cannonau Corp., established in 2007 and formerly known as Pacific Blue Energy Corp., transitioned its focus to the development of cannabidiol (CBD) based products in August 2019. Headquartered in Skaneateles, New York, the company operates within the specialty and generic drug manufacturing industry, specifically targeting the burgeoning CBD market. Cannonau Corp. aims to capitalize on the increasing consumer interest in CBD for various health and wellness applications. As a relatively small player with only 4 employees, Cannonau Corp. faces the challenge of competing with larger, more established companies in the pharmaceutical and wellness sectors. The company's success hinges on its ability to innovate, develop effective CBD products, and establish a strong market presence in a competitive landscape. The company's evolution from Pacific Blue Energy Corp. signals a strategic shift towards the healthcare sector, specifically focusing on the potential of cannabidiol-based therapies and products.
What Products and Services Does CNNC Offer?
- Develop cannabidiol (CBD) based products.
- Focus on the healthcare sector with CBD applications.
- Operate as a specialty and generic drug manufacturer.
- Engage in research and development for new CBD formulations.
- Market and distribute CBD products to consumers.
- Explore potential therapeutic applications of CBD.
How Does CNNC Make Money?
- Develop and formulate CBD-based products.
- Market and sell these products directly to consumers or through retail channels.
- Generate revenue through product sales.
- Potentially license or partner for distribution and manufacturing.
What Industry Does CNNC Operate In?
Cannonau Corp. operates in the Drug Manufacturers - Specialty & Generic industry, specifically targeting the cannabidiol (CBD) market. This market has experienced rapid growth in recent years, driven by increasing consumer awareness of CBD's potential health benefits. However, the industry is also characterized by intense competition and evolving regulatory landscapes. Companies like ACUR, AZFL, CBDX, FIORF, and FLHLF also compete in this space. Cannonau Corp.'s success depends on its ability to differentiate its products and navigate the complex regulatory environment.
Who Are CNNC's Key Customers?
- Individuals seeking alternative health and wellness solutions.
- Consumers interested in the potential therapeutic benefits of CBD.
- Retailers and distributors of health and wellness products.
- Potential partnerships with healthcare providers.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 36 |
| 2026-08-26 | 36 |
| 2026-08-29 | 36 |
| 2026-09-01 | 36 |
| 2026-09-04 | 36 |
| 2026-09-07 | 36 |
| 2026-09-10 | 36 |
What changed?
The score has stayed at 36.
Over the same 18 days the stock moved +50.0%.
Company Profile
Cannonau Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Skaneateles, US. The company is led by CEO Markwin Maring. CNNC has traded publicly since 2010.
Key Financial Metrics
CNNC trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Cannonau Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CNNC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on the growing CBD market.
- Potential for innovative product development.
- Strategic shift towards healthcare applications.
- Small size allows for agility and adaptability.
Bear Case
- Limited financial resources.
- Small team and limited operational capacity.
- Lack of established brand recognition.
- Dependence on a single product category (CBD).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CNNC Latest News
No recent news available for CNNC.
CNNC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CNNC.
Price Targets
Wall Street price target analysis for CNNC.
CNNC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CNNC; grades run from A+ (80-100) to F (below 30).
Leadership: Markwin Maring
CEO
Markwin Maring serves as the CEO of Cannonau Corp., leading a small team of 4 employees. As the CEO, he is responsible for the overall strategic direction and operational management of the company, guiding its focus on developing cannabidiol-based products. His leadership is crucial for navigating the competitive CBD market and achieving the company's growth objectives.
Track Record: Due to limited information, Markwin Maring's specific achievements, strategic decisions, and company milestones under his leadership at Cannonau Corp. are currently unknown. Evaluating his track record requires further data on the company's performance and strategic initiatives since he assumed the role of CEO.
CNNC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cannonau Corp. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in these companies.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 2007.
- Company has a website and contact information.
- Company has a stated business focus (CBD products).
- Company has a CEO and a small team of employees.
- Company has undergone a name change to reflect its current focus.
CNNC Healthcare Stock FAQ
Is CNNC a good stock?
Stock Expert AI does not rate CNNC buy, sell or hold. Cannonau Corp. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about CNNC stock?
There is currently no available analyst coverage for Cannonau Corp. (CNNC). As a small, OTC-listed company with a limited operating history, CNNC does not attract coverage from major financial analysts. Investors should rely on their own independent research and due diligence to assess the company's potential and risks.
What are the key factors to evaluate for CNNC?
Evaluate CNNC on fundamentals, analyst consensus, and risk factors. P/E: 0.00x vs the S&P 500's ~20-25x. Cannonau Corp. presents a speculative investment opportunity within the high-growth CBD market. Not financial advice.
How frequently does CNNC data refresh on this page?
CNNC's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CNNC's recent stock price performance?
Cannonau Corp. (CNNC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on the growing CBD market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CNNC overvalued or undervalued right now?
Cannonau Corp. (CNNC) trades at 0.00x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CNNC?
Yes, most major brokerages offer fractional shares of Cannonau Corp. (CNNC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CNNC's earnings and financial reports?
Cannonau Corp. (CNNC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CNNC earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Cannonau Corp. due to its OTC listing and small size.
- Financial data is limited, making it difficult to assess the company's true value and potential.